Aeterna Zentaris (AEZS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aeterna Zentaris Reports Second Quarter Financial and Operating Results
August 13, 2015 4:15 PM EDTStrong fundamentals; pace of transformation accelerates; dilution negatively impacts stock price
All amounts are in US Dollars
Second quarter key developments
Data and Safety Monitoring Board recommends continuation of ZoptEC Phase 3 study of zoptarelin doxorubicin; patient enrollment completed; second interim results expected in early October 2015 Macrilen confirmatory Phase 3 study initiated Saizen® co-promotion agreement concluded; promotional activities launched on July 27, subsequent to quarter-end Global optimization program successfully completed; significant reduction of expenses at Frankfurt office through lease... More